Related Experiment Videos
Neurodevelopment in pediatric HIV infection. The use of CAT/CLAMS. Clinical Adaptive Test/Clinical Linguistic and
R C Wachtel1, V J Tepper, D Houck
1Department of Pediatrics, University of Maryland School of Medicine, Baltimore.
Insights
The Clinical Adaptive Test/Clinical Linguistic and Auditory Milestone Scale (CAT/CLAMS) effectively monitors neurodevelopment in infants at risk for pediatric neuro-AIDS. This tool helps identify developmental differences in HIV-infected children.
Area of Science:
- Pediatric Neurology
- Infectious Diseases
- Developmental Pediatrics
Background:
- Pediatric neuro-AIDS can be the initial clinical sign of HIV infection in infants born to infected mothers.
- Early detection of neurodevelopmental delays is crucial for managing HIV-exposed children.
Purpose of the Study:
- To evaluate the Clinical Adaptive Test/Clinical Linguistic and Auditory Milestone Scale (CAT/CLAMS) as a monitoring tool for pediatricians.
- To assess the ability of CAT/CLAMS to detect neurodevelopmental differences in children at risk for HIV.
Main Methods:
- The study involved administering the CAT/CLAMS to children at risk for HIV infection.
- Neurodevelopmental outcomes were assessed at 12 and 18 months of age.
- CAT/CLAMS results were compared with the Bayley Scales of Infant Development.
Main Results:
- The CAT/CLAMS successfully identified neurodevelopmental differences between HIV-infected and uninfected children at 12 and 18 months.
- Strong correlations were observed between CAT/CLAMS and the Bayley Scales of Infant Development.
- The findings support the utility of CAT/CLAMS in early developmental screening.
Conclusions:
- The CAT/CLAMS is a valuable tool for pediatricians monitoring neurodevelopment in children at risk for pediatric neuro-AIDS.
- Integrating CAT/CLAMS into routine examinations can aid in the early identification of developmental issues in HIV-exposed infants.
Abstract:
Pediatric neuro-AIDS may be the first clinical manifestation of HIV infection in children born to HIV-infected mothers. As part of the neurodevelopmental examination of children, the Clinical Adaptive Test/Clinical Linguistic and Auditory Milestone Scale (CAT/CLAMS) was investigated as a tool for pediatricians to use to monitor the development of children at risk for HIV infection. The CAT/CLAMS was found to detect neurodevelopmental differences between HIV-infected and uninfected children at 12 and 18 months of age. Good correlations were found between the CAT/CLAMS and concurrently administered Bayley Scales of Infant Development. These findings suggest that the CAT/CLAMS should be considered as a part of the neurodevelopmental examination of children at risk for pediatric neuro-AIDS.